NBCI Search

NBCI Seeks Newly Diagnosed Men and Women Breast Cancer Patients Who Are Members of Our Churches

Image of two women, one older, one younger and more athletic We would like to inform you of a study for men and women with breast cancer using Ribociclib (Kisqali� ) and Letrozole (Femara� ), two drugs that are already approved by the FDA (the US Food and Drug Administration). This combination of drugs is available on the market for certain breast cancer patients, but is still considered experimental for others. This study is called CompLEEment-1 (protocol number CLEE011A2404).

How the Public Learned About the Infamous Tuskegee Syphilis Study

In this 1950's photo released by the National Archives, a nurse writes on a vial of blood taken from a participant in a syphilis study in Tuskegee, Ala. As the fight over reforms to the American health-care system continues this week, Tuesday marks the 45th anniversary of a grim milestone in the history of health care in the U.S.

On July 25, 1972, the public learned that, over the course of the previous 40 years, a government medical experiment conducted in the Tuskegee, Ala., area had allowed hundreds of African-American men with syphilis to go untreated so that scientists could study the effects of the disease.

Understanding Options for Blood Cancers

  • Are you a Patient looking for Disease/Treatment Information?
  • Home Clinical Trials or Standard Treatment?
Topics Covered
  • The role of clinical trials in blood cancer treatment
  • How clinical trials are designed
  • How to determine the best treatment option for you
  • Talking to your healthcare team about treatment options

John P. Leonard, MD
Associate Dean for Clinical Research
Weill Cornell Medical College
New York, NY
March 18, 2015


Q&A Session

Program Slides pdf 114kb

Transcript pdf 129kb

Leukemia and Lymphoma Society logo

Clinical Trials

Health Emergency Declaration (HED)

This is "The Year of Clinical Trial Diversity"!

As you know, we have been working to develop some new resources to help promote diversity in clinical trials. We now have five new public service announcements, a blog, and an infographic that you can use to encourage minorities to join clinical trials. The videos feature Shirley Miller, who is living with sickle cell disease, or Dr. Luciana Borio, Acting Chief Scientist at FDA. They share their views on why diversity in clinical trials matter and encourage patients to learn more. This is important because sometimes minorities may respond differently to medical products. If participation remains low, disparities may continue to exist because of lack of available information about differences in response to treatments- particularly for diseases where minorities are adversely impacted.

We have developed a communications toolkit (see attached) to help you become a "Clinical Trials Champion" in sharing this important message with your community. In the attached toolkit, you will find draft social media messages, sample email/newsletter and blog, and graphics to help promote these efforts.

Let's inspire minority audiences to learn more about clinical trials! Commissioner Rob Califf, M.D. dedicated 2016 to improving minority participation in clinical trials. I hope that you can join us in promoting this effort. For more information about this initiative, please contact me at jovonni.spinner@fda.hhs.gov.

Shirley's Story: How to Find Information about Clinical Trials

Shirley's Story: Getting Access to Cutting Edge Therapies

Shirley's Story: You Don't Have to be Sick to Participate

Shirley's Story: Diversity is Critical to Making Better Medical Products

Shirley's Story: Diversity is Critical to Making Better Medical Products (LONG)

Dr. Luciana Borio: FDA's Role in Increasing Clinical Trial Diversity

Interview with Cariny Nunez, FDA Public Health Advisor [Spanish language]